Dana-Farber/Boston Children’S Cancer

In this video, Tracy T. Batchelor, MD, head of the department of neurology at Brigham and Women's Hospital, discusses the targeted therapies available or in development that target specific mutations in gliomas.

Adoptive cellular therapies such as chimeric antigen receptor T-cell therapy have transformed the landscape of care for patients with relapsed or refractory hematologic malignancies.

Cincinnati Children’s Hospital Medical Center has been ranked the No. 1 children’s hospital for cancer in the country.

In this video, Patrick Wen, MD, professor of neurology at Harvard Medical School and director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, discusses novel and experimental treatments for brain cancer.

In this video, Patrick Wen, MD, professor of neurology at Harvard Medical School and director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, discusses current challenges and opportunities in glioma treatment.

In this video, Patrick Wen, MD, professor of neurology at Harvard Medical School and director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, discusses current challenges and opportunities in glioma treatment.

In this video, Patrick Wen, MD, professor of neurology at Harvard Medical School and director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, discusses how diagnostic techniques for brain cancer are evolving.

In this video, Patrick Wen, MD, professor of neurology at Harvard Medical School and director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute, discusses promising new brain cancer treatments.

Despite an overall positive safety outlook, the scope of potential toxicities related to chimeric antigen receptor T-cell therapy remains unclear due to lack of long-term follow-up.

Several clinicians will be honored at this year’s Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, scheduled for Feb. 15-19 in Orlando.